Login to Your Account

Clinic Roundup

Monday, December 12, 2011
• Gilead Sciences Inc., of Foster City, Calif., said top-line Phase III results showed that elvitegravir, an integrase inhibitor in development for HIV, was noninferior to the integrase inhibitor raltegravir after two years of therapy in treatment-experienced patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription